California Researchers Receive Grant for Retinal Grafts
The National Eye Institute is funding a project to develop 3D-bioprinted retinal grafts for vision loss.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Should government funding prioritize the development of advanced 3D-bioprinting technologies for medical treatments?
Dr. Johnson V. John has been awarded an R56 grant from the National Eye Institute to support the development of 3D-bioprinted retinal grafts. The research aims to combat vision loss caused by conditions like age-related macular degeneration and retinitis pigmentosa.
Why it matters
This funding is intended to advance specific scientific projects and generate essential preliminary results for future R01 grant applications. The work holds promise for developing new regenerative treatments for degenerative eye diseases.
The project utilizes Filamented Light 3D bioprinting technology to construct grafts. These are engineered using stem cell-derived photoreceptor precursor cells and supporting retinal cells.
The players
Dr. Johnson V. John
The lead researcher who secured the grant to develop innovative retinal graft technologies.
National Eye Institute
A federal agency under the National Institutes of Health that funds vision research and programs.
Terasaki Institute for Biomedical Innovation
A research center that focuses on engineering innovative solutions for health and medicine.
University of California, Irvine
A public research university participating in the collaboration to advance retinal graft technology.
University of Southern California
A private research university partnering on the study to address degenerative eye conditions.
The details
Researchers are investigating whether specific engineered graft architectures can improve transplanted cell survival and functional recovery. The project is a collaboration between the Terasaki Institute for Biomedical Innovation, the University of California, Irvine, and the University of Southern California.
Timeline
October 30, 2026: The R56 grant award was officially announced.
1 to 2 years: The project will receive research support over this period.
The Tech Race
This project aligns with the broader push toward regenerative medicine and advanced bioprinting techniques as viable alternatives to traditional transplants. It marks a departure from legacy surgical methods, positioning these institutions at the forefront of bio-engineered ocular therapies.
While this research remains in preclinical stages, its success could eventually provide new treatment options for patients with currently untreatable macular degeneration. The technology represents a shift toward highly personalized, lab-grown solutions that may simplify future medical procedures.
The takeaway
This grant highlights the vital role of bridge funding in moving complex bio-engineering concepts from the laboratory toward clinical application. Advancing 3D-printed tissues continues to be a critical focus area for scientists seeking to replace damaged or lost human biological functions.
Further reading
Learn more about the latest breakthroughs in the field at Biotech.
Source note: This article includes information reported by News-Medical.
Live Poll
Should government funding prioritize the development of advanced 3D-bioprinting technologies for medical treatments?
